

# Novel Drug Delivery System Market to Reach \$67.3Bn by 2031, Growing at 21.2% CAGR | DataM Intelligence

*Novel Drug Delivery System Market to reach \$67.3B by 2031, growing at 21.2% CAGR due to nanotech, biologics, and patient-driven drug delivery solutions.*

NEW YORK, NY, UNITED STATES, May 30, 2025 /EINPresswire.com/ -- Market Overview

The [Novel Drug Delivery System Market](#) is experiencing a

transformative boom, fueled by advances in nanotechnology, targeted therapies, and rising patient-centric healthcare. NDDS enhances the therapeutic effectiveness of

medications by controlling the rate, time, and place of drug release. From liposomal delivery and microneedles to inhalable nanoparticles and implantable devices, these innovations are revolutionizing how treatments are administered for chronic diseases, cancer, and infectious illnesses. Valued at USD 21.2 billion in 2024, the market is projected to soar to USD 67.3 billion


by 2031, expanding at a CAGR of 21.2% during the forecast period.

“

Novel drug delivery systems aren't just making treatments smarter they're redefining how and where healing begins in the human body.”

*DataM Intelligence*

compliant drug delivery solutions.



## Market Drivers

The number of people affected by chronic diseases like cancer, diabetes, and cardiovascular disorders is steadily rising.

Increased demand for painless, targeted, and patient-

Advancements in nanotechnology, biologics, and mRNA-based therapies.

Strong regulatory support and expedited FDA approvals for innovative delivery platforms.

Surge in R&D spending by pharma giants and biotechnology firms.

Rising worldwide use of self-administration devices in home-based healthcare settings.

Expansion of biologic drug pipelines needing advanced delivery formats.

Get Premium Sample Pdf : <https://www.datamintelligence.com/download-sample/novel-drug-delivery-system-market>

### Key Players

The NDDS landscape features robust competition from both pharma giants and biotech innovators, including:

Abbott Laboratories

Pfizer Inc

Johnson & Johnson Inc

F. Hoffmann-La Roche AG

Bristol-Myers Squibb

Novartis AG

Baxter

Spectrum Pharmaceuticals Inc

Boston Scientific Corporation

AstraZeneca PLC

These companies are investing in targeted drug delivery, liposomal carriers, and personalized therapeutic platforms to gain a competitive edge.

### Market Segmentation

By Technology:

- Nanoparticles
- Liposomes
- Prodrugs
- Micelles
- Hydrogels
- Others

By Route of Administration:

- Oral
- Injectable
- Pulmonary
- Transdermal
- Ocular
- Nasal
- Implantable

By Application:

- Oncology
- Infectious Diseases
- Cardiovascular Disorders
- Diabetes
- Neurology
- Others

By End User:

- Hospitals & Clinics
- Homecare Settings
- Research & Academic Institutes
- Others

Latest News of USA

April 2024: Johnson & Johnson launched a wearable transdermal patch for chronic pain that adjusts drug release via smartphone integration.

May 2024: Pfizer received FDA approval for a new oral nanoparticle-based oncology treatment with enhanced absorption rates.

July 2024: Boston Scientific began clinical trials for its implantable drug-eluting device aimed at cardiovascular therapy.

## Latest News of Japan

March 2024: Takeda Pharmaceuticals partnered with Kyoto University to explore intranasal drug delivery for neurodegenerative diseases.

June 2024: Japan's PMDA approved a microneedle patch for influenza vaccination developed by a Tokyo-based biotech startup.

August 2024: Osaka University initiated a research project on biodegradable implants for delivering cancer drugs.

## Key Developments

Jan 2024: AstraZeneca filed for EMA approval of its liposome-based lung cancer therapy.

Feb 2024: Novartis unveiled an oral insulin capsule with controlled-release features.

Mar 2024: Baxter debuted a polymer-coated drug reservoir for dialysis patients.

Apr 2024: Boston Scientific's nano-gel delivery system for atrial fibrillation entered Phase II trials.

May 2024: Spectrum Pharmaceuticals announced progress on their implantable slow-release oncology patch.

## Conclusion

The Novel Drug Delivery System Market is poised to redefine modern medicine with precision-targeted, patient-friendly technologies that improve drug efficacy and reduce side effects. The global momentum backed by strong R&D investments, patient demand, and regulatory encouragement is accelerating the shift from traditional administration routes to cutting-edge platforms. With major players like Abbott, Pfizer, and Roche at the forefront, the NDDS space is expected to evolve rapidly across applications, driving better outcomes in both developed and emerging healthcare systems.

## Related Reports :

[Anesthesia Ultrasound Systems Market Outlook \(2024-2031\)](#)

[Anesthesia Monitoring Devices Market Analysis \(2024 - 2031\)](#)

Sai Kumar

DataM Intelligence 4market Research LLP

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/817479877>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.